Mr. Zakrzewski has over 30 years of experience as an executive in the biotechnology and pharmaceutical industry. He currently serves on the Board of Directors of a number of publicly & privately held companies. He is the founder of a number of biotechnology companies, and is involved in a number of philanthropic activities.  During his operating career he was Chairman and CEO of Amarin Pharmaceuticals, a publicly traded company focused on the development and commercialization of cardiovascular drugs based on Omega 3‘s from 2010 to 2013, successfully developing and launching Vascepa®. Mr. Zakrzewski served as a Venture Partner with Orbimed, in 2010 and 2011. Prior to this, he was Chairman, President & Chief Executive Officer of Xcellerex, a privately held company focusing on commercializing its proprietary next generation biologics manufacturing technology for biotherapeutics and vaccines from 2007 to 2010. Xcellerex was sold to GE Healthcare.  Mr. Zakrzewski also served as the Chief Operating Officer of Reliant Pharmaceuticals, a specialty pharmaceutical company focused on cardiovascular drugs from 2005 to 2007, overseeing the launch of Lovaza®. Reliant Pharmaceuticals was sold to GSK plc. Prior to this, Mr. Zakrzewski served in a variety of executive level positions at Eli Lilly & Company for 17 years including R&D, manufacturing, finance and business development. His most recent position had global responsibility for all business and corporate development.  Mr. Zakrzewski is an inventor on numerous patents and has been involved in or led financings amounting to several billion dollars for both private and public companies. Over his career, he has served as a member of the board of directors of over 25 companies, with a number of successful exits for shareholders. He received a BS in Chemical Engineering from Drexel University in 1986, an MS in Biochemical Engineering from Drexel University in 1988, and an MBA in Finance in 1992 from Indiana University.

Chris Carpenter has more than two decades of clinical and laboratory experience in oncology. He focuses on clinical-stage product companies, particularly in oncology, rare diseases, and other specialty therapeutic areas.

Before joining Sofinnova in 2022, Chris was Chief Medical Officer at CatamaranBio. Previously, he was the Chief Medical Officer at Rubius Therapeutics, a company developing red blood cells as therapeutics. Prior to Rubius, Chris was Senior Vice President and Head of the Cancer Epigenetics group at GlaxoSmithKline, where he was responsible for the overall strategy, as well as the identification and validation of new epigenetic targets and advancing novel therapies through clinical proof of concept. While at GlaxoSmithKline, Chris also led the development of Votrient (pazopanib). Before GlaxoSmithKline, he was at Merck and led the development of MK-4827, which became Tesaro’s Zejula. Prior to Merck, Chris led a laboratory at Harvard Medical School and the Beth Israel Deaconess Medical Center for 14 years. He is board certified in internal medicine and medical oncology.

Chris earned his B.S. from Stanford University, and received his M.D. and Ph.D.  (pharmacology) degrees from the University of Southern California. He completed a residency in internal medicine at UT Southwestern, his hematology/oncology fellowship at Massachusetts General Hospital, and a post-doctoral fellowship in Lewis Cantley’s laboratory.

Jackie has more than 12 years of experience in healthcare across a range of functions including venture investing, business development and scientific research. She joined Abingworth in 2018 and works across the teams in the Boston, London and Menlo Park offices to source and evaluate new investment opportunities and support existing venture investments through exit.

Prior to joining Abingworth, Jackie was a Senior Associate at SV Health Investors. She was formerly in the Business Development Group at Genentech with primary responsibility for partnering activities in neuroscience. Her transactions span a broad spectrum of deal structures and therapeutic areas, including technology and platform in-licenses and research collaborations. Jackie has a PhD in Neuroscience from Stanford School of Medicine and an MBA from Stanford Graduate School of Business.

Christina Isacson is a Partner of Lightstone Ventures and focuses on investments in the biopharmaceutical sector. Christina has spent nearly 20 years in the biotech industry across operational roles and in venture capital. She brings experience in creating, launching, building and operating early stage biotechnology companies including Magenta Therapeutics (NASDAQ:MGTA) and Decibel Therapeutics (NASDAQ:DBTX).

Before joining Lightstone in 2021, Christina was part of the founding team and Chief Business Officer at Magenta Therapeutics where she was accountable for portfolio strategy and management, program management, business development, alliance management and commercial strategy. Prior to Magenta, Christina was Principal at Third Rock Ventures, an early-stage life sciences venture capital firm. At Third Rock, Christina focused on new company formation, due diligence, and led business development efforts more broadly on behalf of Third Rock. Prior to being part of the founding teams of Magenta and Decibel, Christina held operational roles at Ironwood Pharmaceuticals (NASDAQ:IRWD) in corporate development. In addition, she has held venture roles with Boston University’s Technology Development Fund and with Accelerator Corp (Fund I).

Dr. Riedel was executive chairman and chief executive officer of Apinyx. He was formerly president and CEO of Naurex, the predecessor company acquired by Allergan and from which Aptinyx and its technology were spun out. Prior to Naurex, Dr. Riedel served various roles at Baxter International including corporate vice president and chief science and innovation officer. Previously, he was head of worldwide biotechnology and held a number of scientific management positions at Hoechst Marion Roussel (now Sanofi).

Dr. Riedel serves on the board of Jazz Pharmaceuticals, Eton Pharmaceuticals, and the Illinois Biotechnology Innovation Organization. He served on the board of directors of Ariad Pharmaceuticals until the company was acquired in February 2017, and the board of Cerevel Therapeutics until the company was acquired in August of 2024.

Dr. Riedel is a member of the Austrian Academy of Sciences and served on Governor Pat Quinn’s Illinois Innovation Council. He is an adjunct professor at Boston University School of Medicine and Northwestern University’s Fienberg School of Medicine and, prior to moving into the industry, was an associate professor of medicines at Boston University School of Medicine and a visiting professor at the Massachusetts Institute of Technology.

Dr. Riedel received a Diplomar and PH.D. from the University of Frankfurt and was a postdoctoral fellow at Harvard University.

Patrick Ritschel is an experienced executive and entrepreneur with over 30 years of experience in business management, biotechnology, and technology licensing. Mr. Ritschel has founded multiple biotechnology companies, including Torque Bio, a circular RNA company, and StrideBio, an AAV gene therapy company where he also served as President for several years. He was an angel investor and played an instrumental role in the formation of gene therapy company Bamboo Therapeutics (acquired by Pfizer in 2016). Mr. Ritschel spent his early career with Monsanto Enviro-Chem Systems, Inc. in St. Louis and Hong Kong. He was a member of the management team that bought out the business, and upon the subsequent sale of the company to DuPont, he joined DuPont as Director of Business Development.

He is active in the rare disease community and currently serves on the Board of Directors of the Friedreich’s Ataxia Research Alliance (FARA).

Mr. Ritschel holds a B.S. in Mechanical Engineering from the University of Illinois Urbana-Champaign, cum laude, and an M.B.A. from Washington University in St. Louis.

Jennifer Wellman has more than 20 years’ experience in adeno-associated viral (AAV) vector gene therapy research and development. She is currently Chief Operating Officer at Akouos, a precision genetic medicine company focused on developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals who live with disabling hearing loss. Previously, Ms. Wellman served as Akouos’s Senior Vice President of Regulatory and Quality. Prior to that, Ms. Wellman was Co-founder, Head of Product Development Strategy, and Head of Regulatory Strategy at Spark Therapeutics, Inc., a member of the Roche Group and a fully integrated, commercial gene therapy company. While at Spark, and in her earlier role as Director of Regulatory for the Center for Cellular and Molecular Therapeutics at Children’s Hospital of Philadelphia (CHOP), Ms. Wellman led the regulatory and clinical development for several AAV gene therapies, including Luxturna®, the first FDA-approved gene therapy for a genetic condition. Prior to her time at CHOP, she served as an Associate Scientist at Avigen, Inc.

Ms. Wellman holds an M.S. from the University of New Haven and an Honours B.S. in microbiology and immunology from Queen’s University (Canada).

Patrick Ritschel is an experienced executive and entrepreneur with over 30 years of experience in business management, biotechnology, and technology licensing. Mr. Ritschel has founded multiple biotechnology companies, including Torque Bio, a circular RNA company, and StrideBio, an AAV gene therapy company where he also served as President for several years. He was an angel investor and played an instrumental role in the formation of gene therapy company Bamboo Therapeutics (acquired by Pfizer in 2016). Mr. Ritschel spent his early career with Monsanto Enviro-Chem Systems, Inc. in St. Louis and Hong Kong. He was a member of the management team that bought out the business, and upon the subsequent sale of the company to DuPont, he joined DuPont as Director of Business Development.

He is active in the rare disease community and currently serves on the Board of Directors of the Friedreich’s Ataxia Research Alliance (FARA).

Mr. Ritschel holds a B.S. in Mechanical Engineering from the University of Illinois Urbana-Champaign, cum laude, and an M.B.A. from Washington University in St. Louis.

Kenji Fujita, MD, is an internist and cardiologist with over 20 years of experience in academic medicine and industry. His experience spans preclinical to post-marketing research across a wide range of disease areas and therapeutic platforms. Throughout his career, Dr. Fujita has led five successful regulatory filings.

Prior to joining Atsena, Dr. Fujita was Vice President of Clinical Development at Alnylam Pharmaceuticals, where he led the successful filing and registration of OXLUMO™, the first treatment for hyperoxaluria, in addition to leading clinical programs in hypertension and liver disease. He has also held clinical development roles at Alexion Pharmaceuticals, where he led neurology and rare metabolic disease programs, and Merck, where he worked in cardiovascular clinical development and served as the Clinical Development Lead of the Emerging Markets Research and Development group. Earlier in his career, Dr. Fujita was a Junior Engagement Manager at McKinsey & Company.

Dr. Fujita has authored more than 20 peer-reviewed articles and currently serves as an Assistant Professor in Clinical Medicine at Robert Wood Johnson University Hospital. He completed a residency in internal medicine and a fellowship in cardiology at Columbia University and is board certified in both specialties. Dr. Fujita holds an MD from Harvard Medical School and AB, summa cum laude, in Biochemical Sciences from Harvard College.

Dr. Shannon E. Boye is a Professor and Associate Chief of the Division of Cellular and Molecular Therapy in the University of Florida’s Department of Pediatrics. She received her BS in marine biology with a minor in chemistry from Fairleigh Dickinson University in 2001. She graduated with a PhD in Neuroscience from the University of Florida in 2006. Her thesis work involved developing viral vectors for the treatment of retinal disease, specifically GUCY2D Leber Congenital Amaurosis (LCA1). Following a postdoctoral fellowship and research assistant professorship Dr. Boye was appointed as tenure track Assistant Professor in the University of Florida’s Department of Ophthalmology (2012). In 2016, she received tenure and was promoted to the rank of Associate Professor. In 2020, she transferred to the Department of Pediatrics where she is now Associate Chief of the Division of Cellular and Molecular Therapy.

Dr. Boye has authored over 50 peer-reviewed manuscripts, multiple textbook chapters, is actively involved in grant and manuscript review, and is the recipient of several major awards including the ARVO Foundation/Merck Innovative Ophthalmology Research Award in Gene Therapy and Eye Disease, the Foundation Fighting Blindness Board of Director’s Award, the ARVO Foundation/Pfizer Ophthalmics Carl Camras Translational Research Award, a University of Florida Research Foundation Professorship, and the Gund Harrington Scholar Award for excellence in gene therapy research.